SUMMARY
Patient-controlled analgesia (PCA) with opioids has been widely used for postoperative pain management. However, this modality is associated with a high incidence of nausea and vomiting. Previous studies report that 50 to 80% of patients who received PCA experienced nausea and vomiting [1] [2] [3] [4] . These symptoms are unpleasant and can increase hospital stay and health care costs 5 . Single dose anti-emetic prophylaxis is often inadequate in managing nausea and vomiting 6 . A number of studies have found that adding ondansetron to morphine PCA effectively reduces the prevalence of opioid-induced nausea and vomiting [7] [8] [9] [10] . Midazolam is a short-acting benzodiazepine with a rapid onset of action that is widely used for preoperative sedation and co-induction of anaesthesia. A perioperative bolus of midazolam decreases the incidence and severity of postoperative nausea and vomiting (PONV) [11] [12] [13] [14] and a continuous infusion postoperatively is also effective in reducing PONV 15, 16 . However, the effect of midazolam on nausea and vomiting associated with postoperative PCA morphine is unknown. In this study, we compared the effect of midazolam and ondansetron in reducing morphine-induced nausea and vomiting in patients having total abdominal hysterectomy.
MATERIALS AND METHODS
This prospective, randomised, clinical study was approved by the Institutional Review Board of Kyungpook National University Hospital. Ninety ASA physical status I or II non-smoking female patients, aged 35 to 60 years and undergoing total abdominal hysterectomy, were enrolled. Written informed consent was obtained from all patients. Patients with a history of drug abuse, allergies to any of the study drugs, liver or renal dysfunction, previous PONV or motion sickness, who had received anti-emetic medication within 24 hours or who complained of preoperative nausea or vomiting were excluded.
Age, weight, height, duration of anaesthesia and of post-anaesthesia care unit (PACU) stay were documented. The night before surgery, patients were given instruction about the PCA device. No premedication was given. The anaesthetic regimen and postoperative pain management were standardised, with general anaesthesia induced with intravenous (IV) propofol 2 mg/kg, fentanyl 1.0 µg/kg and rocuronium 1 mg/kg and maintained with 70% nitrous oxide and 1.0 to 1.5% isoflurane (end-expiratory). glycopyrrolate 7 µg/kg and pyridostigmine 30 µg/kg were administered intravenously to reverse residual neuromuscular blockade.
A computer-generated sequence was used to randomise patients in equal ratios to the three groups. All patients received an initial loading dose of the study drug over five minutes at their first request for pain medication in the PACU, followed by administration of the study drug as per protocol. group M (n=30) received IV morphine 5 mg plus midazolam 1 mg as the loading dose, followed by PCA with a mixture of midazolam 0.4 mg/ml and morphine 1 mg/ml. group O (n=30) received IV morphine 5 mg plus ondansetron 4 mg followed by PCA with a mixture of ondansetron 0.2 mg/ml and morphine 1 mg/ml. group C (n=30) received IV morphine 5 mg followed by PCA morphine 1 mg/ml.
The loading doses of drugs were prepared in 10 ml normal saline and the total PCA volume was 55 ml. An anaesthetist not involved in the study prepared the study medication. Data were collected at one, four, eight, 16 and 24 hours postoperatively by a study-blinded anaesthetist. The pain intensity scores were measured at rest with a visual analogue scale from 0 (no pain) to 10 (the worst possible pain). The PCA pump (Abbott Ambulatory Infusion Manager ® Plus, Abbott Laboratories, North Chicago, IL, USA) was programmed to deliver morphine 1 mg per demand with a five-minute lockout interval and no basal infusion. If a patient reported a pain score >4 and requested additional analgesia, IV ketorolac 30 mg was administered every eight hours as needed.
The primary study outcome was the presence of PONV during the 24-hour observation period. Nausea was defined as a subjectively unpleasant sensation associated with awareness of the urge to vomit, while vomiting was defined as the forceful expulsion of gastric contents from the mouth. For the purpose of data collection, retching (same as vomiting but without expulsion of gastric contents) was considered vomiting. If a patient asked for rescue anti-emetic or experienced vomiting, IV metoclopramide 10 mg was administered.
Sedation was assessed using a four-point scale (0=awake, 1=mild sedation, easily aroused with verbal command; 2=moderate sedation, easily woken with light stimulation; 3=deep sedation, difficult to rouse with shaking) 17 . A sedation score of 3 or respiratory depression (respiratory rate <8 /minute) lasting more than 10 minutes was regarded as clinically unacceptable, was reported and the patient switched to an alternative analgesic modality. Side-effects were documented.
Based upon previous studies 2, 3 , the predicted incidence of nausea and vomiting in this study was about 80%. A reduction by half to 40% was considered clinically significant. Based on an α error of 0.05 and the β error of 0.2, a minimum sample size of 30 patients per group was estimated to be required. One-way analyses of variance were conducted to examine differences among the three groups with respect to continuous variables. If a significant difference was found, Tukey post hoc comparisons were used to detect intergroup differences. The Kruskal-Wallis test was used to determine differences among the three groups with respect to ordinal variables and post hoc comparisons between groups were made using the Mann-Whitney U-test. Categorical data were analysed using the chi-square test or Fisher's exact test. For study outcomes, logistic regression provided odds ratios comparing groups M and O with group C. All follow-up analyses were corrected for the number of simultaneous contrasts using Bonferroni's adjustment. A P value of less than 0.05 was considered significant.
RESULTS
Patient demographics, duration of anaesthesia and of PACU stay were similar among groups ( Table 1 ). The frequency of nausea and vomiting is shown in Table 2A and odds ratios for groups M and O vs C in Table 2B . During the first 24 hours Values are mean ± SD. No significant differences. PACU=post-anaesthesia care unit.
after surgery, the incidence of PONV was significantly higher in group C (70%) than amongst those receiving midazolam (group M 26.7%, P <0.05) or ondansetron (group O 36.7%, P <0.05). The incidence of nausea was significantly lower in groups M and O compared with group C (P <0.05).
There was no significant difference between groups M and O. During the 24-hour postoperative period, the incidence of mild sedation in group M was higher than in groups O or C (P <0.05). However, the incidence of moderate sedation did not differ between groups (Table 2A) and severe sedation or respiratory depression was not observed in any group. Dizziness and pruritus were other side-effects reported, with no significant differences between groups (Table 2A) .
Pain scores were not different among the groups (Figure 1 ), nor were there any differences in PCA morphine use or rescue analgesic use (Table 3) . Values are mean ± SD and number of patients (%). No significant differences. 
DISCUSSION
In this study, midazolam and ondansetron reduced the frequency of PONV to a similar degree among patients receiving morphine PCA. In women undergoing gynaecological surgery with IV morphine PCA, the incidence of PONV is 50 to 80% 3,4 and our control group showed an incidence consistent with this.
The aetiology of PONV is probably multifactorial and predictive factors among adults having general anaesthesia with inhalational anaesthetic drugs include female gender, history of PONV or motion sickness, non-smoking status, surgical duration of >60 minutes and use of postoperative opioids 18 . The frequency of PONV is 10 to 20% for patients with zero or one risk factor and 40 to 80% for patients with two or more risk factors 18 . Therefore, we controlled these factors within our study design, with all patients being non-smokers having total abdominal hysterectomy performed by the same team of anaesthetists and surgeons. The groups were balanced for risk factors, increasing confidence that differences found can be attributed to the study interventions.
Ondansetron, a selective 5-hydroxytryptamine type 3 receptor antagonist, is effective in reducing the risk of PONV in high-risk surgical patients 5 . A combination of ondansetron (0.13 to 0.32 mg) and morphine (1 mg) is effective against PONV associated with PCA [7] [8] [9] [10] and the incidence of 36% among patients receiving ondansetron 4 mg followed by a mixture of ondansetron 0.2 mg and morphine 1 mg is similar to that in previous studies 9, 10 . The anti-emetic effect of midazolam has been evaluated in a number of studies [11] [12] [13] [14] [15] [16] . Di Florio and goucke 15 showed that a bolus (1 mg) followed by an infusion at 1 mg/h was effective against persistent PONV, refractory to other anti-emetics. Sanjay et al 16 found that a midazolam infusion at 0.02 mg/kg/hour after a 1 mg bolus was more effective than ondansetron 0.1 mg/kg IV every six hours in preventing PONV after cardiac surgery. In previous studies [19] [20] [21] the mean morphine consumption after total abdominal hysterectomy was 50 to 60 mg during the first 24 hours. In this study the PCA mixture of midazolam 0.4 mg/ml and morphine 1 mg/ml was commenced after a bolus of midazolam 1 mg and morphine 5 mg. This ratio of midazolam to morphine (0.4:1) was derived by dividing 24 mg midazolam by 55 mg of morphine. In our study the 24 hour mean consumption of morphine and midazolam was 53 mg and 20 mg respectively and this regimen with midazolam significantly reduced PONV compared with control.
Despite the relative short half-life of midazolam, Bauer et al 13 showed that premedication with IV midazolam 0.04 mg/kg reduced PONV for up to 24 hours. Unlugenc et al 11 suggested the anti-emetic effect of midazolam lasted longer than the sedative effect. We chose to use a loading dose followed by PCA infusion, so we cannot distinguish any differential effects of one versus the other. The antiemetic mechanism of action of midazolam is not fully understood. Postulated mechanisms include glycine-mimetic inhibitory effects, potentiation of the inhibitory effects of gamma-aminobutyric acid, augmentation of adenosinergic effects, inhibition of dopamine release and augmentation of adenosine-mediated inhibition of dopamine in the chemoreceptor trigger zone 15, 22 . The side-effects of anti-emetics may limit their use. The prominent side-effects of midazolam and morphine are sedation and respiratory depression, so co-administration might produce synergistic effects. In our study mild sedation was more common in the midazolam group but did not reduce morphine use, while there was no difference observed between groups with respect to moderate sedation and deep sedation or respiratory depression. Although PCA morphine is considered safe, respiratory depression can occur, especially in high-risk patients including elderly people who are especially sensitive to this effect from midazolam 23 . Therefore we suggest that this regimen warrants careful patient monitoring.
In this study population, at a midazolam to morphine ratio of 0.4:1 via IV PCA, midazolam significantly decreased the incidence of nausea and vomiting. However, the optimal ratio of midazolammorphine admixture for the prophylaxis of PCA morphine-induced PONV with minimisation of side-effects needs evaluation in future studies.
In conclusion, in this study midazolam was as effective as ondansetron in preventing opioidinduced nausea and vomiting following total abdominal hysterectomy and had acceptable sideeffects.
